Subgroup meta-analysis
| Unfavourable outcome† (%) (99% CI) | Heterogeneity Q value/I2 | p Value (het)* | p Value (sig) | |
|---|---|---|---|---|
| Quality of study | ||||
| High quality studies (n=9‡, 2704 patients, 3027 aneurysms) | 9.9 (4.9% to 19.0%) | 68.1/88.3% | <0.0001 | <0.0001 |
| Low quality studies (n=51, 7141 patients, 8012 aneurysms) | 6.1 (4.2% to 8.7%) | 323.2/84.5% | <0.0001 | |
| Origin of study | ||||
| North America (n=24, 4901 patients, 5343 aneurysms) | 9.4 (5.9% to 14.6%) | 223.8/89.7% | <0.0001 | <0.0001 |
| Europe (n=17, 1351 patients, 1764 aneurysms) | 4.5 (2.4% to 8.4%) | 38.7/58.7% | 0.001 | |
| Asia (n=18, 3583 patients, 3920 aneurysms) | 5.2 (3.1% to 8.6%) | 94.2/90.0% | <0.0001 | |
| Midyear of treatment | ||||
| 1990–2000 (n=22, 1711 patients, 1853 aneurysms) | 8.0 (4.7% to 13.4%) | 99.1/78.8% | <0.0001 | <0.0001 |
| 2001–2011 (n=38, 8134 patients, 9186 aneurysms) | 6.0 (4.1% to 8.7%) | 282.3/86.9% | <0.0001 | |
| Age (years) | ||||
| Mean age >55 (n=9, 433 patients) | 11.8 (6.8% to 19.8%) | 19.8/64.7% | 0.006 | 0.18 |
| Mean age ≤55 (n=5, 93 patients) | 8.2 (3.1% to 20.0%) | 1.7/0% | 0.79 | |
| Location | ||||
| Anterior (n=17, 2461 patients) | 5.7 (2.3% to 13.3%) | 151.9/90.1% | <0.001 | <0.0001 |
| Posterior (n=13, 549 patients) | 15.6 (7.4% to 30.1%) | 52.3/80.9% | <0.001 | |
| Fundus size (mm) | ||||
| <10 (n=6, 240 patients) | 4.0 (1.7% to 8.8%) | 0.2/0% | 1 | <0.0001 |
| 10–25 (n=7, 195 patients) | 12.1 (7.0% to 19.9%) | 4.9/0% | 0.6 | |
| >25 (n=7, 156 patients) | 26.5 (8.5% to 58.3%) | 19.9/74.9% | 0.001 | |
*p Value associated with the χ2 test for heterogeneity.
†Unfavourable outcome: morbidity, including mortality.
‡Number of studies.